[HTML][HTML] Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus–associated lower respiratory tract�…
KE Fleming-Dutra�- MMWR. Morbidity and mortality weekly report, 2023 - cdc.gov
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants.
Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV�…
Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV�…
Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial
Z Bebia, O Reyes, R Jeanfreau…�- The Journal of�…, 2023 - academic.oup.com
Background In a phase 1/2 study, a maternal respiratory syncytial virus vaccine candidate
(RSVPreF3) demonstrated an acceptable safety profile and efficiently increased RSV�…
(RSVPreF3) demonstrated an acceptable safety profile and efficiently increased RSV�…
RSV prefusion f protein–based maternal vaccine—preterm birth and other outcomes
I Dieussaert, J Hyung Kim, S Luik, C Seidl…�- …�England Journal of�…, 2024 - Mass Medical Soc
Background Vaccination against respiratory syncytial virus (RSV) during pregnancy may
protect infants from RSV disease. Efficacy and safety data on a candidate RSV prefusion F�…
protect infants from RSV disease. Efficacy and safety data on a candidate RSV prefusion F�…
[HTML][HTML] Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on�…
JM Jones�- MMWR. Morbidity and mortality weekly report, 2023 - cdc.gov
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants.
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting�…
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting�…
A randomized phase 1/2 study of a respiratory syncytial virus prefusion F vaccine
EE Walsh, AR Falsey, DA Scott…�- The Journal of�…, 2022 - academic.oup.com
Background Protection against human respiratory syncytial virus (RSV) remains an unmet
need potentially addressable by maternal immunization. This phase 1/2 study evaluated a�…
need potentially addressable by maternal immunization. This phase 1/2 study evaluated a�…
Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes
M Son, LE Riley, AP Staniczenko, J Cron…�- JAMA Network�…, 2024 - jamanetwork.com
Importance A nonadjuvanted bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF
[Pfizer]) protein subunit vaccine was newly approved and recommended for pregnant�…
[Pfizer]) protein subunit vaccine was newly approved and recommended for pregnant�…
[HTML][HTML] Meeting report: WHO consultation on respiratory syncytial virus (RSV) vaccine development, Geneva, 25–26 April 2016
BK Giersing, RA Karron, J Vekemans, DC Kaslow…�- Vaccine, 2019 - Elsevier
Respiratory syncytial virus (RSV) is a leading viral cause of respiratory morbidity and
mortality in infants and young children worldwide. Low and middle income countries (LMICs)�…
mortality in infants and young children worldwide. Low and middle income countries (LMICs)�…
Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants
B Kampmann, SA Madhi, I Munjal…�- …�England Journal of�…, 2023 - Mass Medical Soc
Background Whether vaccination during pregnancy could reduce the burden of respiratory
syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is�…
syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is�…
Prefusion F protein–based respiratory syncytial virus immunization in pregnancy
EAF Sim�es, KJ Center, ATN Tita…�- …�England Journal of�…, 2022 - Mass Medical Soc
Background Respiratory syncytial virus (RSV), a major cause of illness and death in infants
worldwide, could be prevented by vaccination during pregnancy. The efficacy�…
worldwide, could be prevented by vaccination during pregnancy. The efficacy�…
Three dose levels of a maternal respiratory syncytial virus vaccine candidate are well tolerated and immunogenic in a randomized trial in nonpregnant women
TF Schwarz, C Johnson, C Grigat…�- The Journal of�…, 2022 - academic.oup.com
Background Respiratory syncytial virus (RSV) causes respiratory tract infections, which may
require hospitalization especially in early infancy. Transplacental transfer of RSV antibodies�…
require hospitalization especially in early infancy. Transplacental transfer of RSV antibodies�…